Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company’s web site at www.hanabiosciences.com.
- 17 years ago
QualityStocks
Hana Biosciences, Inc. (NASDAQ: HNAB)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…